IO Biotech, Inc. (IOBTQ) Cash & Equivalents (2020 - 2025)

IO Biotech (IOBTQ) has 6 years of Cash & Equivalents data on file, last reported at $30.7 million in Q3 2025.

• Quarterly Cash & Equivalents fell 61.76% year-over-year to $30.7 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $30.7 million (down 61.76% YoY) and the FY2024 annual result came in at $60.0 million, down 58.08% from the prior year.
• Cash & Equivalents rose to $30.7 million in Q3 2025, from $28.1 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $211.5 million in Q4 2021 to a low of $28.1 million in Q2 2025.
• A 5-year average of $106.8 million and a median of $110.1 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2021 — Cash & Equivalents soared 6112.36% — and 2025, when it sank 72.08%.
• Tracing IOBTQ's Cash & Equivalents over 5 years: stood at $211.5 million in 2021, then plunged by 32.59% to $142.6 million in 2022, then advanced by 0.42% to $143.2 million in 2023, then slumped by 58.08% to $60.0 million in 2024, then tumbled by 48.92% to $30.7 million in 2025.
• The last three Cash & Equivalents figures came in at $30.7 million (Q3 2025), $28.1 million (Q2 2025), and $37.1 million (Q1 2025), per Business Quant data.